Ask Onix
Updated February 13, 2026 - Investigation reveals widespread harm from dopamine agonist drugs, prompting calls for stronger warnings.
Twelve years of ruin: A solicitor's fall
Frances arrived at work one morning in 2012 to learn her husband, Andrew, a solicitor in a Manchester suburb, had been arrested on fraud charges. Police were simultaneously searching their family home, where their two children lived. His legal practice, which managed finances for elderly clients with dementia, was cordoned off with crime scene tape as staff watched records being seized.
Investigators later discovered Andrew had stolen £600,000 from 13 clients, most over 80. The money funded adult webcam subscriptions, sex workers, and compulsive antique purchases. One victim, an 87-year-old care home resident, died shortly after the theft, leaving her estate unable to cover funeral costs. Andrew's actions, later attributed to a Parkinson's medication, destroyed his family and led to two suicides.
The hidden toll of dopamine agonists
Andrew's case is not isolated. Over the past year, The Meta Times has interviewed dozens of families whose lives were upended by impulse control disorders (ICDs) triggered by dopamine agonist drugs. These medications, prescribed 1.5 million times by English GPs last year alone, treat Parkinson's disease, Restless Legs Syndrome, and other conditions by boosting dopamine-a chemical regulating movement and reward-seeking behavior.
A 2010 study found one in six Parkinson's patients on these drugs develops ICDs, which can manifest as compulsive gambling, shopping, or hypersexuality. Yet many patients and families report receiving no warnings about these risks. Layla Moran, chair of the UK Parliament's Health Select Committee, called the findings "devastating" and has demanded the drugs regulator review official warnings.
From miracle drug to nightmare
Andrew was diagnosed with Parkinson's in the early 2010s. When tremors worsened, doctors prescribed Pramipexole, a dopamine agonist. His family described the drug's effects as "miraculous"-his tremors subsided, and he resumed playing tennis. But within a year, his behavior changed dramatically.
In the 12 months after starting the medication, Andrew made nearly 500 payments to adult webcam sites, spent £100,000 on one platform alone, and paid £80,000 to sex workers in four months. His phone contained contacts for 90 escorts. He also bought £85,000 worth of antiques on eBay in six months. Frances, his wife, said she noticed compulsive shopping but had no idea of the scale until his arrest.
In 2013, after collapsing at home, Andrew was hospitalized. There, a doctor asked Frances if she knew Pramipexole could cause impulsive behaviors. She said the revelation was a "terrible shock," as she had attended all his medical appointments and never been warned.
A family shattered
Andrew's arrest in 2012 triggered a cascade of tragedies. His son, Harry, who had long-standing mental health struggles, was sectioned after the scandal. Weeks later, he took his own life. In 2015, Andrew pleaded guilty to fraud. The judge acknowledged the medication's role in his behavior but noted he had still managed other aspects of his legal practice competently. Andrew was sentenced to four years in prison.
Frances and Andrew divorced during his incarceration. After his release in 2017, he moved into sheltered housing. His Parkinson's symptoms worsened after he stopped the medication, and he struggled during COVID-19 lockdowns. In October 2020, he died by suicide. Neither his death nor Harry's is recorded in the UK's Yellow Card system, which tracks drug side effects.
Systemic failures and calls for change
Families affected by dopamine agonists describe losing life savings, homes, and loved ones. Many say they were never warned about the risks, despite 2017 guidelines requiring doctors to inform Parkinson's patients and monitor for ICDs. Some patients prescribed the drugs since then report still receiving no warnings.
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) told The Meta Times it has no plans to update warnings, arguing that sexual behaviors are "individualized" and cannot be exhaustively listed. GSK, which first licensed dopamine agonists for Parkinson's in the UK, said its drug had been approved globally and prescribed over 17 million times. It shared safety concerns with regulators in 2003 but did not comment on current warnings.
"It's not just a side effect that affects an individual-it's affecting families and communities, creating new victims. What does 'impulsive behavior' mean, and how likely is it? Patients don't have that information."
Layla Moran, Chair, Health Select Committee
Moran criticized the Yellow Card system as inadequate for reporting shame-inducing side effects. The UK government called the findings "hugely concerning."
Unanswered questions and lingering pain
Frances and her daughter, Alice, have relocated but still grapple with the fallout. "I had my life taken away: my home, my community, but above all my son," Frances said. "I just don't have the words to say how devastating that is."
For support related to the issues in this story, visit the BBC Action Line.
